---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-007283"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T17:52:13.193542+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences reports 74% avg volume reduction in benign thyroid nodule ablation at 15-22 months

## Summary
- 21 patients monitored 15-22 months; average 74% volume reduction of benign thyroid nodules with no regrowth.
- 100% of patients highly satisfied with cosmetic appearance; 95% highly satisfied overall; no serious adverse events.
- Data presented by Prof. Stefano Spiezia at North American Society for Interventional Thyroidology 2026 meeting.
- CEO Paul LaViolette said non-cardiac nsPFA plans will be clarified in second half of 2026.

## SEC filing metadata
- accession: 0001437749-26-007283
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774926007283/0001437749-26-007283-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774926007283/plse20260306_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-007283
- JSON: https://secwatch.observer/filing/0001437749-26-007283.json
- Plain text: https://secwatch.observer/filing/0001437749-26-007283.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.